CN Bio - About the company
CN Bio is a series B company based in Cambridge (United Kingdom), founded in 2009. It operates as a Develops organ-on-a-chip platforms for drug discovery. CN Bio has raised $71.8M in funding from CITIC, with a current valuation of £*****. The company has 42 active competitors, including 22 funded and 1 that has exited. Its top competitors include companies like Emulate, Okomera and Hesperos.
Company Details
Develops organ-on-a-chip platforms for drug discovery. The PhysioMimix OOC benchtop device is a Lab-on-a-Chip system that helps in vitro studies in fields including oncology, infectious diseases, metabolism, and inflammation, develop therapeutic antibodies/proteins, and cellular therapies, to investigate drug metabolism, toxicity, and drug-drug interactions. Also have Liver-On-a-Chip, barrier models, and others.
- Website
- cn-bio.com
- Social
- Email ID
- *****@cn-bio.com
- Phone Number
- +44 **********
- Registered Address
- 30 UPPER HIGH STREET,THAME,OXFORDSHIRE,OX9 3EZ
Key Metrics
Founded Year
2009
Location
Cambridge, United Kingdom
Stage
Series B
Total Funding
$71.8M in 14 rounds
Latest Funding Round
Post Money Valuation
£***** as on Jul 26, 2024
Ranked
2nd among 42 active competitors
Annual Revenue
£3.47M as on Dec 31, 2024
Employee Count
59 as on May 31, 2026
Legal entities associated with CN Bio
CN Bio is associated with 3 legal entities given below:
Legal Entity Name | Date of Incorporation | Revenue | Latest Employee Count | Documents |
|---|---|---|---|---|
Cn Bio Innovations Limited CIN: 6517359 , United Kingdom, Active | Feb 27, 2008 | $4.43M (As on Dec 31, 2024) | 49 (As on Dec 31, 2024) | |
CN Bio Innovations Ltd CIN: 6517359 , Germany, Active | Feb 27, 2008 | $4.43M (As on Dec 31, 2024) | 43 (As on Dec 31, 2023) | |
CN BIO INNOVATIONS, INC. CIN: 6772402 , United States, Active | May 02, 2022 | - | - | - |
Sign up to download CN Bio's company profile
CN Bio's funding and investors
CN Bio has raised a total funding of $71.8M over 14 rounds. Its first funding round was on Jan 29, 2010. Its latest funding round was a Series B round on Apr 23, 2024 for $*****. 2 investors participated in its latest round. CN Bio has 14 institutional investors and 1 angel investor.
Here is the list of recent funding rounds of CN Bio:
Filter this list
Filter this listDate of Funding | Funding Amount | Round Name | Post-Money Valuation | Revenue Multiple | Lead Investors | Other Investors |
|---|---|---|---|---|---|---|
Apr 23, 2024 | 6529906 | Series B | 5830689 | 7897035 | 9364707 | 4969382 |
Mar 02, 2021 | 5600637 | Grant (prize money) | 1208921 | 8163350 | 8428548 | |
Feb 18, 2021 | 8848598 | Series A | 2812592 | 6013974 | 5871657 | 3165946 |
Access funding benchmarks and valuations. Sign up today!View details of CN Bio's funding rounds and investors
CN Bio's founders and board of directors
Founder? Claim ProfileCN Bio's Board of Directors
CN Bio's board has 8 active members. Maureen Sheila Helen Coleman and Paul Robert Brooks are part of team and Yuexing Su, Hok Hei Charles Chong, Michael David Courtney Scales, Wang Yin, Andy Tse Po Shing and Tong Cheuk Fung are independent board members.Here is the list of CN Bio's board of directors:
Name | Type | Representing | Status | Duration |
|---|---|---|---|---|
sdp{{go | Team | - | Current | 8y 8m |
Investor | - | Current | 16y 0m | |
Independent board member | - | Current | 11y 11m | |
ozclcnc | Independent board member | - | Current | 4y 4m |
oyoxndt | Independent board member | - | Current | 8y 9m |
ea{{lmm | Independent board member | - | Current | 3y 7m |
lzorzvv | Independent board member | - | Current | 1y 6m |
afufhvi | Independent board member | - | Current | 2y 7m |
CN Bio's employee count trend
CN Bio has 59 employees as of May 26. Here is CN Bio's employee count trend over the years:
Uncover CN Bio's growth story! Sign up today!
Access Tracxn on any website
Install Tracxn ExtensionOur Google Chrome extension lets you view company details while browsing their websites
CN Bio's Competitors and alternates
Top competitors of CN Bio include Emulate, Okomera and Hesperos. Here is the list of Top 10 competitors of CN Bio, ranked by Tracxn score:
Get insights and benchmarks for competitors of 2M+ companies! Sign up today!
Rank | Company Details | Short Description | Total Funding | Investors | Tracxn Score |
|---|---|---|---|---|---|
1st | Emulate 2013, Boston (United States), Series E | Developer of in vitro models for drug development | $225M | 59/100 | |
2nd | CN Bio 2009, Cambridge (United Kingdom), Series B | Develops organ-on-a-chip platforms for drug discovery | $71.8M | 58/100 | |
3rd | Developer of a device for in vitro cancer testing using a microfluidic chip | $11.2M | 54/100 | ||
4th |  Hesperos 2015, Orlando (United States), Funding Raised | Developer of organ-on-a-chip solutions for preclinical testing | - | 53/100 | |
5th | Nortis 2007, Woodinville (United States), Acquired | Developer of platform for generating small segments of human tissues and organs in microfluidic chips | $10.7M | 50/100 | |
6th | Mimetas 2013, Leiden (Netherlands), Series B | Develops microfluidics-based organ-on-a-chip tissue models | $28.9M | 45/100 | |
7th | _1574840379393.png?devicePixelRatio=2&height=30&width=30){kind=logo} Obatala Sciences 2017, New Orleans (United States), Series A | Provider of research enabling products and services to research centers | $3.53M | 43/100 | |
8th |  Cellbox Labs 2020, Riga (Latvia), Seed | Provider of organ-on-chip platform for drug discovery and development | $1.01M | 43/100 | |
9th | Developer of microfluidic devices for industrial applications | $14M | 40/100 | ||
10th |  Mepsgen 2019, Seoul (South Korea), Series C | Developer of human organ model chips for pharmaceutical development | $29.3M | 40/100 |
Get insights and benchmarks for competitors of 2M+ companies! Sign up today!Looking for more details on CN Bio's competitors? Click here to see the top ones
CN Bio's Investments and acquisitions
CN Bio has made no investments or acquisitions yet.
News related to CN Bio
Filter this listMedia has covered CN Bio for a total of 2 events in the last 1 year, 2 of them have been about company updates.
•
CN Bio launches all-in-one Organ-on-a-chip systemEuropean Pharmaceutical Manufacturer•Oct 15, 2025•CN Bio
•
CN Bio enhances ADME services with computational modeling for accelerated drug discoveryEuropean Pharmaceutical Manufacturer•Sep 02, 2025•CN Bio
•
CN Bio and Pharmaron Establish Long-Term Strategic PartnershipBusiness Wire•Apr 24, 2025•Pharmaron, CN Bio
•
CN Bio Launches PhysioMimix DILI Assay Kit: Human 24, for Enhanced Preclinical Toxicology TestingBusiness Wire•Feb 04, 2025•CN Bio
•
•
•
CN Bio Raises $21 Million Series B FinancingEuropean Pharmaceutical Manufacturer•Apr 23, 2024•CN Bio, Pharmaron, CN Innovations
•
•
•
Get curated news about company updates, funding rounds, M&A deals and others. Sign up today!Are you a Founder ?
FAQs about CN Bio
Explore our recently published companies
- MVP Partners - Germany based, 2021 founded, Unfunded company
- Nanointech - Wonju based, 1994 founded, Unfunded company
- Cnmcheltenham - United Kingdom based, Unfunded company
- URWERK - Geneve based, 1997 founded, Unfunded company
- Gementerprise - United Kingdom based, Unfunded company
- Cjsnyc - Unfunded company
